Literature DB >> 5649733

A formalism for calculation of absorbed dose from radionuclides.

R Loevinger, M Berman.   

Abstract

Mesh：

Year:  1968        PMID： 5649733     DOI： 10.1088/0031-9155/13/2/306

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN： 0031-9155            Impact factor:   3.609


× No keyword cloud information.
  8 in total

1.  Radiation dosimetry of intralymphatic radiotherapy.

Authors:  G M Owen
Journal:  Proc R Soc Med       Date:  1969-06

2.  Application of 212Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation.

Authors:  Kwon Yong; Martin Brechbiel
Journal:  AIMS Med Sci       Date:  2015-08-18

3.  The Influence of Early Measurements Onto the Estimated Kidney Dose in [(177)Lu][DOTA(0),Tyr(3)]Octreotate Peptide Receptor Radiotherapy of Neuroendocrine Tumors.

Authors:  Andreas Delker; Harun Ilhan; Christian Zach; Julia Brosch; Franz Josef Gildehaus; Sebastian Lehner; Peter Bartenstein; Guido Böning
Journal:  Mol Imaging Biol       Date:  2015-10       Impact factor: 3.488

4.  Monte Carlo track-structure for the radionuclide Copper-64: characterization of S-values, nanodosimetry and quantification of direct damage to DNA.

Authors:  J Carrasco-Hernández; J Ramos-Méndez; B Faddegon; A R Jalilian; M Moranchel; M A Ávila-Rodríguez
Journal:  Phys Med Biol       Date:  2020-07-27       Impact factor: 3.609

5.  PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates.

Authors:  Darren R Veach; Claire M Storey; Katharina Lückerath; Katharina Braun; Christian von Bodman; Urpo Lamminmäki; Teja Kalidindi; Sven-Erik Strand; Joanna Strand; Mohamed Altai; Robert Damoiseaux; Pat Zanzonico; Nadia Benabdallah; Dmitry Pankov; Howard I Scher; Peter Scardino; Steven M Larson; Hans Lilja; Michael R McDevitt; Daniel L J Thorek; David Ulmert
Journal:  Clin Cancer Res       Date:  2021-01-13       Impact factor: 12.531

Review 6.  The potential and hurdles of targeted alpha therapy - clinical trials and beyond.

Authors:  Jörgen Elgqvist; Sofia Frost; Jean-Pierre Pouget; Per Albertsson
Journal:  Front Oncol       Date:  2014-01-14       Impact factor: 6.244

7.  EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands.

Authors:  Katarina Sjögreen Gleisner; Nicolas Chouin; Pablo Minguez Gabina; Francesco Cicone; Silvano Gnesin; Caroline Stokke; Mark Konijnenberg; Marta Cremonesi; Frederik A Verburg; Peter Bernhardt; Uta Eberlein; Jonathan Gear
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-14       Impact factor: 10.057

8.  Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.

Authors:  Sally L George; Nadia Falzone; Sarah Chittenden; Stephanie J Kirk; Donna Lancaster; Sucheta J Vaidya; Henry Mandeville; Frank Saran; Andrew D J Pearson; Yong Du; Simon T Meller; Ana M Denis-Bacelar; Glenn D Flux
Journal:  Nucl Med Commun       Date:  2016-05       Impact factor: 1.690
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.